Marnie Sizemore

Marnie Sizemore is an experienced healthcare professional with a strong background in launching treatments for rare diseases. Currently serving as a Rare Disease Specialist at BioCryst Pharmaceuticals, Inc., Marnie successfully launched ORLADEYO, the first oral prophylactic treatment for Hereditary Angioedema. Previous roles include Senior Clinical Specialist at Genentech, where Marnie played a crucial role in launching ESBRIET for Idiopathic Pulmonary Fibrosis and XOLAIR for allergic asthma. Marnie's expertise extends to launching first-in-class therapies at Bayer HealthCare and Affymax, as well as promoting various treatments across several companies, including Genzyme Therapeutics and Enzon BioPharmaceuticals. Marnie holds a foundation in education from Missouri State University and Colorado State University.